NewAmsterdam Pharma (NAMS) EBIT (2023 - 2025)
Historic EBIT for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$55.1 million.
- NewAmsterdam Pharma's EBIT fell 12054.55% to -$55.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.9 million, marking a year-over-year decrease of 1020.89%. This contributed to the annual value of -$176.3 million for FY2024, which is 364.98% up from last year.
- Per NewAmsterdam Pharma's latest filing, its EBIT stood at -$55.1 million for Q3 2025, which was down 12054.55% from -$35.6 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's EBIT registered a high of -$25.0 million during Q3 2024, and its lowest value of -$68.9 million during Q1 2025.
- For the 3-year period, NewAmsterdam Pharma's EBIT averaged around -$47.2 million, with its median value being -$49.6 million (2023).
- In the last 5 years, NewAmsterdam Pharma's EBIT skyrocketed by 4954.8% in 2024 and then tumbled by 12054.55% in 2025.
- NewAmsterdam Pharma's EBIT (Quarter) stood at -$51.1 million in 2023, then rose by 15.36% to -$43.2 million in 2024, then dropped by 27.56% to -$55.1 million in 2025.
- Its EBIT was -$55.1 million in Q3 2025, compared to -$35.6 million in Q2 2025 and -$68.9 million in Q1 2025.